ReviewHeart failure reviews2026
Wearable Cardioverter-Defibrillator in Adult Congenital Heart Disease: A Bridge to Decision, Recovery, and Advanced Therapies.
Review in Heart failure reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Consensus recommendation of the Austrian Society of Cardiology: anatomy, pathophysiology, diagnosis and treatment of arrhythmias in adult patients with congenital heart disease].Wiener klinische Wochenschrift · 2026Review
- The Role of Wearable Devices in the Management of Congenital Heart Disease.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sudden cardiac death (SCD) remains a major cause of mortality among adults with congenital heart disease (ACHD). Risk stratification for malignant ventricular arrhythmias in this population is challenging because of the heterogeneity of anatomical substrates, lifelong haemodynamic changes, and the limited predictive accuracy of currently risk models. Furthermore, implantation of an implantable cardioverter-defibrillator (ICD) in ACHD patients is frequently complicated by anatomical constraints, limited venous access, and a significant burden of device-related complications, including infection involving prosthetic material. Several transient cardiac or systemic conditions-including haemodynamic deterioration, acquired myocardial disease, infections, inflammatory states, pregnancy, endocrine disturbances, or peri-procedural phases-may temporarily increase arrhythmic risk or impair ventricular function. In these scenarios, the indication for permanent ICD may be uncertain or premature. The wearable cardioverter-defibrillator (WCD) provides a non-invasive option for temporary protection against life-threatening ventricular arrhythmias while allowing time for clinical stabilization, diagnostic reassessment, and individualized decision-making. This review summarizes the pathophysiological rationale, available evidence, and potential clinical applications of WCD therapy in ACHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.